Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer

RT + C significantly improved DFS, but not OS, with no increase in long-term toxicity, compared with RT alone for resected, intermediate-risk SCCHN. RT + C is an appropriate option for carefully selected patients with HPV-negative disease.